The inhibitory quotient (IQ) of human immunodeficiency virus (HIV) protease inhibitors (PIs), which is
The virological efficacy of protease inhibitors (PIs) in patients infected by the human immunodeficiency virus (HIV) is dependent on both their pharmacodynamic and their pharmacokinetic properties. In vitro high and sustained plasma (or cell) concentrations are needed to maximally suppress viral replication. The dose administered in HIV-infected patients should provide such concentrations.
The inhibitory quotient (IQ), defined as the ratio of the trough drug concentration in serum (C min ) to viral susceptibility expressed as an inhibitory concentration (ideally, the 90% inhibitory concentration [IC 90 ]), has been used to estimate the antiviral potency of PIs in vivo (24) . This parameter has also been proposed to optimize the dosing regimen of treatment-experienced patients (12, 20) . Although there is a strong theoretical rationale for using the IQ, the practical value of this parameter is controversial. First, there are few prospective studies of the relationship between IQ and virological response (22) . Second, there is no consensus method for calculating this parameter (1, 24, 27) . Standard calculations estimate IQ from both the plasma drug concentration and virus susceptibility. However, several pharmacokinetic and virological issues remain unsolved. In most pharmacokinetic studies, the total drug concentration in plasma is measured, whereas the active component is the free (protein-unbound) fraction. Furthermore, the addition of human albumin to the cell culture medium increases the IC 90 in vitro. In summary, either the total concentration or the protein-adjusted concentration, and either the standard or the serum-adjusted IC 90 , can be used to calculate the IQ. More recently, a "genotypic IQ" (GIQ) was proposed as the ratio of the plasma concentration to the number of mutations on the viral protease gene. Indeed, genotypic resistance assays can be performed rapidly and are less costly than phenotypic resistance assays (11) . Both genotypic and phenotypic IQs are predictive of changes in the HIV RNA level in treatmentexperienced patients (5, 9, 11, 17, 22, 23, 31) , but only one study of the predictive value of the IQ is available with data from patients treated with two ritonavir-boosted PIs (8) .
We aimed at estimating the relationship between the IQs of amprenavir and lopinavir and the virological response after 2, 6, and 26 weeks of treatment in a group of heavily pretreated patients who participated in the French National Agency for AIDS Research (ANRS) 104 trial. Several methods for calculating IQs were compared with the viral phenotype and genotype for their ability to predict changes in plasma viral load.
(This study was presented in part at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 14 to 17 September 2003 [2a] .)
MATERIALS AND METHODS
Study design and study population. The ANRS 104 study was a prospective, randomized, open-label, multicenter trial involving patients with CD4 counts of Ͻ500/mm 3 and plasma HIV RNA at Ͼ10,000 copies/ml after receiving successive antiretroviral treatments including at least two PIs and one nonnucleoside reverse transcriptase inhibitor. The main objective of this trial was to compare the clinical efficacies and tolerabilities of a combination of amprenavir and lopinavir-ritonavir in treatment-experienced patients (26) . The study was divided into two periods. For the first 2 weeks (period 1), patients were randomized to receive, in addition to their ongoing nucleoside reverse transcriptase inhibitors (NRTI), (i) lopinavir-ritonavir (400/100 mg twice a day [BID]) or lopinavirritonavir (400/100 mg BID) plus ritonavir (100 mg BID) or (ii) amprenavir (600 mg BID) plus ritonavir (100 mg BID) or amprenavir (600 mg BID) plus ritonavir (200 mg BID). From week 3 to week 26 (period 2), all the patients received amprenavir plus lopinavir-ritonavir, with or without an additional boost of ritonavir (100 mg BID). The NRTIs were optimized on the basis of viral genotyping results and previous antiretroviral exposure. The genotype was interpreted for each inhibitor by using the 2001 update of the ANRS algorithm. Patients were recruited from 16 French clinical AIDS units. All patients signed an Ethics Committee-approved informed consent form. Patients were instructed to take their medication in the morning and evening, with a light meal. Physical examinations, CD4 and CD8 cell counts, and hematological and clinical chemistry measurements were performed at each study visit (weeks Ϫ2, 0, 2, 4, and 6 and then monthly for the subsequent 20 weeks). Blood samples were also drawn at weeks Ϫ2, 0, 2, 6, and 26 for plasma HIV type 1 (HIV-1) RNA, viral genotyping and phenotyping, and drug assays in plasma.
Laboratory measurements. (i) Virological parameters. Plasma HIV-1 RNA was assayed locally at weeks Ϫ2, 0, 2, 4, 6, 14, and 26 by using the Roche Amplicor HIV-1 monitor kit (Roche, France; limit of quantitation, 200 copies/ ml) or the Quantiplex HIV RNA 3.0 assay (Bayer Diagnostics, France; limit of quantitation, 50 copies/ml).
(ii) HIV-1 protease genotyping and phenotyping. Viral genotyping was performed at weeks Ϫ2, 2, 6, and 26 based on direct sequencing of the HIV-1 proteasecoding region and using the consensus technique of the ANRS AC11 resistance group or the TruGene HIV-1 genotyping kit (Visible Genetics, Bayer). The genotype was taken into account only if a complete protease sequence (amino acids 1 to 99) was obtained. Protease sequences from each patient were examined for the presence of mutations associated with protease resistance at the following 21 relevant codons (11) Resistance phenotyping was performed at screening (week Ϫ2) for all the patients and at week 26 for those patients in whom the antiretroviral drug regimen failed and had plasma HIV RNA levels above 50 copies/ml (20/37 patients) according to a recombinant virus assay (Phenoscript; Viralliance) (25) . Results were expressed as the PI concentration inhibiting virus spread by 90% (IC 90 ), in a standard method without added human serum (IC 90 ). In a subgroup of 12 patients who started their study regimen with amprenavir, the amprenavir IC 90 was also determined after adding 40% human serum to the growth medium which contains 10% fetal bovine serum in order to reach a total protein concentration close to that found in human plasma (IC 90ϩserum ).
(iii) Drug assays in plasma. Blood samples were drawn at week 2 and week 6, just before the scheduled drug intake (C min ). The total and unbound amprenavir and total lopinavir C min values were measured by high-pressure liquid chromatography with separation on a C 18 column after liquid/liquid extraction of alkaline plasma and UV detection as described elsewhere (2, 26, 29) . Bound amprenavir and unbound amprenavir were separated by ultrafiltration using Centrifree devices (Amicon, YM-300 filter system; Millipore Corp., Bedford, MA). Amprenavir was then measured in the ultrafiltrate as previously described. The overall day-to-day coefficient of variation was below 12% (2). All concentrations were expressed in ng/ml or mol/liter for IQ calculations.
Calculation of IQs. Phenotypic IQs were calculated as the ratio of the plasma C min of each PI to the IC 90 measured at baseline. For amprenavir, the IC 90 values were determined with or without added protein (IC 90ϩserum or IC 90 ), and both the total C min and unbound C min (C minu ) values were measured. Two methods to adjust for protein binding were tested, namely, C minu and IC 90ϩserum (24) . Amprenavir IQs were therefore calculated as the ratios of C minu /IC 90 (IQ u ) and C min /IC 90ϩserum (IQ serum ).
The GIQ of each PI was calculated as the ratio of the plasma C min corrected for protein binding (C minu ) to the baseline number of protease resistance mutations. The following mutations on the viral protease were considered: L10I/F/ R/V, K20M/R, L24I, D30N, V32I, L33F, M36I, M46I/L, I47A/V, G48V, I50V, F53L, I54L/T/V, L63P, A71I/L/V/T, G73S, V77I, V82A/F/T/S, A84V, N88D/S, and L90M.
During the second treatment period, in which patients received two ritonavirboosted PIs, the combined IQs were calculated as the sum of the phenotypic IQ u for each PI. C minu was not measured but was calculated as the total C min corrected by the average protein binding of amprenavir (10%) (2, 15) and of lopinavir and ritonavir (1%) (3, 4) . The combined GIQ was calculated as the sum of the ratios of C minu /number of protease resistance mutations.
Statistical analysis. The median (range) was used to describe the distribution of amprenavir, lopinavir, and ritonavir parameters and for the different IQ calculations. Univariate linear regression was used to estimate the relation between the decline in viral load (difference between baseline and week 2, 6, or 26) and the different C min , IC 90 , and IQ values. The higher was the proportion of explained variance (r 2 ) of viral load, the better was the model. All statistical tests were run on SAS software (version 8.2; SAS Institute).
RESULTS
Overall, 37 patients were enrolled in the ANRS 104 study. Their baseline characteristics are shown in Table 1 . Twenty- Amprenavir and lopinavir C min values are reported in detail elsewhere (26, 29) and were not related to the virological response. The median unbound amprenavir C minu at week 2 was 177 ng/ml and was not predictive of the virological response at week 2.
In a subgroup of 12 patients who had phenotypic studies (group 2), the amprenavir IC 90 was 57.8 ng/ml (8.7 to 150.9) and increased to 453 ng/ml (33 to 1,105) when measured in the presence of 50% human serum (IC 90ϩserum ). The IC 90ϩserum was a good predictor of the early virological response (week 2, P ϭ 0.006), whereas the IC 90 was not. Amprenavir IQs adjusted for protein binding (IQ u and IQ serum ) were rather similar (2.5 and 3.6, respectively). The relationship with viral load decline at week 2 was slightly better with IQ u than with IQ serum (r 2 ϭ 0.45, P ϭ 0.02 versus r 2 ϭ 0.31, P ϭ 0.06), although those results might be explained by reference to an outlier patient (r 2 ϭ 0.24, P ϭ 0.12 versus r 2 ϭ 0.11, P ϭ 0.31 without the outlier patient).
For the 21 patients treated with lopinavir during the first period, the lopinavir IC 90 was 34.2 ng/ml (0.7 to 330.4) and was a good predictor of the virological response at weeks 2, 6, and 26 (week 2, r 2 ϭ 0.37, P ϭ 0.003; week 6, r 2 ϭ 0.23, P ϭ 0.03; week 26, r 2 ϭ 0.33, P ϭ 0.006). The number of protease mutations (Ͻ5 or Ն5) was related to the virological response throughout the study (at week 2, r 2 ϭ 0.18, P ϭ 0.008; at week 6, r 2 ϭ 0.11, P ϭ 0.046; and at week 26, r 2 ϭ 0.12, P ϭ 0.034) (Fig. 1) . Table 2 shows the virological responses throughout the study as a function of the amprenavir and lopinavir phenotypic IQ and GIQ values measured at week 2 or week 6. The amprenavir GIQ (corrected amprenavir C min at week 2/number of protease mutations at week Ϫ2) was related to the virological response at week 2 (r 2 ϭ 0.66, P ϭ 0.0004) and at week 6 (r 2 ϭ 0.38, P ϭ 0.02). Patients who had a C min -corrected GIQ above 75 had a median decline in HIV RNA of 1.23 log 10 copies/ml (Ϫ2.27; Ϫ0.97) versus 0.19 log 10 copies/ml (Ϫ1.07; 0.15) in patients with a GIQ below 75 (P ϭ 0.005). In contrast, none of the lopinavir IQs were predictive of antiretroviral activity.
None of the phenotypic IQs or GIQs of amprenavir and lopinavir (determined with the C min corrected for protein binding and measured at week 6) were predictive of the viral load decline. However, a combination of the amprenavir and lopinavir GIQs, whether measured either with the standard equation or adjusted for protein binding, and with or without ritonavir, was predictive of the viral response at week 6 but not at the end of the study, as shown on Fig. 2 . Patients who responded at week 6 (plasma HIV RNA Ͻ10,000 versus Ն10,000 copies/ml) had a higher median combined GIQ measured at week 6 (65 versus 29; P ϭ 0.01).
DISCUSSION
A significant proportion of antiretroviral-experienced patients never have optimal viral suppression or experience a viral rebound shortly after starting a new treatment. Our population was heavily pretreated with a high proportion of baseline NRTI ge- notypic resistance; consequently, the efficacy of the combination results essentially from both PIs. Treatment thus needs to be optimized according to viral susceptibility and the plasma PI concentration. This study provides IQ data for two currently used ritonavir-boosted PIs, amprenavir and lopinavir, when administered alone (first 2 weeks of the study) or in combination, in heavily pretreated HIV-infected patients. This is one of the few studies to show that the combined IQ can be a useful predictor in patients who receive ritonavir-boosted dual-PI therapy (8) .
We compared two methods for calculating the phenotypic IQ, which incorporates protein binding. Amprenavir and lopinavir are highly bound to plasma proteins and especially alpha1 acid glycoprotein (90% and 98 to 99%, respectively). As only free drug inhibits viral replication, protein binding affects the potency of these two PIs. ICs measured in vitro must be adjusted for protein binding before extrapolation to the clinical setting. Moreover, ICs suffer from variability due to a lack of standardization of phenotyping methods (14) . There are three methods for adjusting the in vitro IC for protein binding, namely, multiplication of the IC by the free fraction measured in vivo, measurement of the IC in the presence of 50% human serum albumin, and multiplication of the IC by a constant to adjust for assay variations (20) , but none of these methods has been clinically validated. Our results show that, whatever the equation used to calculate IQ (C minu /standard IC 90 or C min /IC 90ϩserum ), the relationship with viral load decline is very similar. The best correlation was obtained with the IQ u ( C minu /IC 90 ). It has previously been demonstrated that measuring and calculating the C minu gives similar results (29) . However, it remains to be determined whether these findings can be extrapolated to PIs other than amprenavir.
We found no relationship between lopinavir or amprenavir exposure and the decline in viral load, in agreement with previous studies (6, 7, 13, 16, 30) . Amprenavir and lopinavir C min values obtained with the ritonavir boost were far higher than the IC 50 reported for wild-type virus (28) and the IC 90 measured at screening. This might explain why plasma concentrations were poorly predictive of the decline in plasma HIV RNA. Compliance with medication was not measured in our study; the amprenavir and lopinavir C min values suggested that it was maximal at week 2 and week 6 but declined thereafter.
Thus, none of the phenotypic IQ values based on concentrations measured at week 6 were predictive of antiviral efficacy.
The GIQ is simpler to measure than the phenotypic IQ. We found that the GIQ of amprenavir was associated with the virological response at week 2 and week 6 but not at week 26. Furthermore the amprenavir GIQ cutoff of 75 could be a useful tool in clinical practice, as previously demonstrated by Marcelin et al. (18) . Our findings confirm that the GIQ, which incorporates both baseline viral resistance and the level of drug exposure in plasma, is superior to drug exposure alone in predicting the virological response to a salvage regimen (18) . However, lopinavir IQs did not correlate with virological efficacy, and our data do not support those reported elsewhere (5, 9, 16) . This is probably because the lopinavir C min values for our patients were sufficiently high not to restrict efficacy (13) , whereas lopinavir concentrations were lower in other studies (5, 9) . In these latter studies, the C min was determined as part of routine therapeutic drug monitoring or observational studies, settings in which compliance is important for overall exposure (5, 9, 16) . One limitation of therapeutic drug monitoring is the wide intrapatient variability of trough concentrations, as recently demonstrated by Nettles et al. (21) and Goujard et al. (10) . Poor compliance and an effect of food may be involved in this variability. We acknowledge that one limitation of our study is that compliance was not measured. However, comparison of trough concentrations measured at weeks 6, 14, and 26 clearly shows that compliance is decreasing from week 6, where concentrations of lopinavir and amprenavir were in the expected range in all patients, in contrast to weeks 14 and 26, where 7 and 6 patients, respectively, had concentrations below the limit of quantification of the assay (26) .
Interestingly, the combined GIQ was predictive of the virological response at week 6, as in the GigHAART trial (8) . This suggests that a combination of two PIs has a strong antiviral effect that might overcome resistance in these strongly pretreated patients. As expected, ritonavir did not participate in the drug effect, as the concentrations used to boost PIs are too low (even though some patients received 200 mg BID). The combined IQ of amprenavir plus lopinavir plus ritonavir was close to the combined IQ of amprenavir plus lopinavir and had the same predictive potential. However, the predictive value of this parameter disappeared at the end of the study, for several possible reasons. In particular, the C min tends to fall, as a negative initial interaction between the two PIs and a decreased compliance tends to reduce their concentrations and exposure levels; additionally, the viral resistance profile is continually evolving (19) . Further studies are needed to determine which viral mutations have the biggest impact on the GIQ and how these mutations can be taken into account in the calculations (30) .
The combined GIQ did not have better predictive value than the number of mutations. In these highly pretreated patients with high PI C min values, the number of PI resistance mutations is a major determinant of virological outcome (5, 13, 16) and in our study was the only factor predictive of the virological response at week 26. Finally, as previously demonstrated (26) , patients with more than five protease resistance mutations or a lopinavir mutation score (13, 14) of higher than 5 at baseline had a significantly poorer virological response than other patients (P ϭ 0.04 and P ϭ 0.006, respectively).
Thus, this study suggests that when treatment compliance is FIG. 2. Relationship between viral load decline at week 6 and combined (lopinavir and amprenavir) GIQ at week 6 (r 2 ϭ 0.12, P ϭ 0.03).
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on June 21, 2017 by guest http://aac.asm.org/ optimal and high PI concentrations are achieved, the viral genotype is the best predictor of virological outcome.
